Leeds Institute for Cardiovascular and Metabolic Medicine, University of Leeds, LS2 9JT Leeds, UK.
Leeds Institute of Data Analytics, University of Leeds, LS2 9JT Leeds, UK.
Eur Heart J Qual Care Clin Outcomes. 2022 Dec 13;9(1):8-15. doi: 10.1093/ehjqcco/qcac067.
The European Society of Cardiology (ESC) EURObservational Research Programme (EORP) Non-ST-segment elevation myocardial infarction (NSTEMI) Registry aims to identify international patterns in NSTEMI management in clinical practice and outcomes against the 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without ST-segment-elevation.
Consecutively hospitalised adult NSTEMI patients (n = 3620) were enrolled between 11 March 2019 and 6 March 2021, and individual patient data prospectively collected at 287 centres in 59 participating countries during a two-week enrolment period per centre. The registry collected data relating to baseline characteristics, major outcomes (in-hospital death, acute heart failure, cardiogenic shock, bleeding, stroke/transient ischaemic attack, and 30-day mortality) and guideline-recommended NSTEMI care interventions: electrocardiogram pre- or in-hospital, pre-hospitalization receipt of aspirin, echocardiography, coronary angiography, referral to cardiac rehabilitation, smoking cessation advice, dietary advice, and prescription on discharge of aspirin, P2Y12 inhibition, angiotensin converting enzyme inhibitor (ACEi)/angiotensin receptor blocker (ARB), beta-blocker, and statin.
The EORP NSTEMI Registry is an international, prospective registry of care and outcomes of patients treated for NSTEMI, which will provide unique insights into the contemporary management of hospitalised NSTEMI patients, compliance with ESC 2015 NSTEMI Guidelines, and identify potential barriers to optimal management of this common clinical presentation associated with significant morbidity and mortality.
欧洲心脏病学会（ESC）的 EURObservational Research Programme（EORP）非 ST 段抬高型心肌梗死（NSTEMI）注册研究旨在确定临床实践中 NSTEMI 管理的国际模式和 2015 年 ESC 急性冠状动脉综合征管理指南推荐的治疗方案下 NSTEMI 患者的结局。
连续纳入 2019 年 3 月 11 日至 2021 年 3 月 6 日期间住院的成年 NSTEMI 患者（n=3620），并在 59 个参与国家的 287 个中心进行前瞻性收集，每个中心的注册时间为两周。该注册研究收集了基线特征、主要结局（院内死亡、急性心力衰竭、心源性休克、出血、卒中和短暂性脑缺血发作以及 30 天死亡率）以及指南推荐的 NSTEMI 治疗干预措施的数据：入院前或入院时的心电图、阿司匹林的院前应用、超声心动图、冠状动脉造影、转诊心脏康复、戒烟咨询、饮食建议以及出院时的阿司匹林、P2Y12 抑制剂、血管紧张素转换酶抑制剂（ACEi）/血管紧张素受体阻滞剂（ARB）、β受体阻滞剂和他汀类药物的处方。
EORP NSTEMI 注册研究是一项针对 NSTEMI 患者进行的护理和结局的国际前瞻性注册研究，它将为住院 NSTEMI 患者的当代管理、对 2015 年 ESC NSTEMI 指南的遵循情况提供独特的见解，并确定这种常见临床表现的最佳管理的潜在障碍，因为其与显著的发病率和死亡率相关。
